Improved (n=109) | Non-improved (n=141) | p Value | |
---|---|---|---|
Male sex | 66 (60.6) | 99 (70.2) | 0.110 |
Age, year | 59.2±12.0 | 62.2±12.2 | 0.055 |
Cigarettes smoked daily, N | 24.1±13.2 | 22.8±11.9 | 0.407 |
Duration of smoking, year | 36.9±13.1 | 40.0±12.7 | 0.060 |
Brinkman Index | 885.7±591.5 | 905.0±564.3 | 0.792 |
TDS score | 8.1±1.5 | 7.3±1.6 | <0.001 |
Baseline exhaled CO, ppm | 13.6±9.3 | 14.3±9.7 | 0.542 |
Changes in exhaled CO, ppm | −9.6±9.2 | −9.6±9.3 | 0.985 |
Body mass index, kg/m2 | 23.0±4.8 | 23.2±4.2 | 0.729 |
Baseline FEV1, % predicted | 73.2±21.8 | 77.9±18.4 | 0.068 |
Baseline FVC, % predicted | 81.0±18.6 | 84.8±14.9 | 0.078 |
FEV1/FVC, % | 73.5±13.7 | 74.6±11.9 | 0.529 |
Changes in FEV1, L | 0.05±0.28 | 0.03±0.21 | 0.580 |
Treated by varenicline | 44 (40.4) | 53 (37.6) | 0.655 |
Quitter | 64 (58.2) | 92 (65.3) | 0.291 |
Mental disorder | 36 (33.0) | 35 (24.8) | 0.155 |
Diabetes mellitus | 19 (17.4) | 27 (19.2) | 0.728 |
Cardiovascular disease | 23 (21.1) | 27 (19.2) | 0.702 |
COPD | 23 (21.0) | 23 (16.3) | 0.334 |
Bronchial asthma | 16 (14.7) | 11 (7.8) | 0.084 |
Cancer | 6 (5.5) | 12 (8.5) | 0.356 |
Data are presented as number (%) or mean±SD.
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; SGRQ, St. George's Respiratory Questionnaire; TDS, Tobacco Dependence Screener test.